The Associate Scientist will support R&D in drug discovery and environmental monitoring. Reports to the Lab Director.
XRpro was founded in 2003 by Ben Warner, and combines proprietary technology with responsive service models in two industries, both of which exploit the core competency of the company: X-ray fluorescence. The technology has applications in high-throughput screening (HTS) for ion channel activity, real-time kinetics of ion channel activities in populations of intact cells, HTS of enzyme inhibitors, and real-time detection of chemical species in industrial effluent.
XRpro® benefits from a solid IP estate, including 30 issued and pending patents developed by the company, as well as several licenses from the Los Alamos National Laboratory where Dr. Warner was a scientist for many years. He holds a Ph.D. in Organic Chemistry from MIT.
CEO, Gary G. Altman, PhD, joined the company in 2013, and comes to XRpro Corp. with a background in leading businesses in drug discovery and in vitro diagnostics. He successfully led a global business at Beckman Coulter and was co-founder of Sequoia Pharmaceuticals of Gaithersburg, MD.
XRpro is composed of two divisons:
- Drug Discovery – Assay development & screening
- Environmental Safety – Real-time, actionable, monitoring of industrial effluents